Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1992 Feb;51(2):152–155. doi: 10.1136/ard.51.2.152

Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus.

A J MacGregor 1, V B Dhillon 1, A Binder 1, C A Forte 1, B C Knight 1, D J Betteridge 1, D A Isenberg 1
PMCID: PMC1005648  PMID: 1550394

Abstract

Fasting cholesterol, triglyceride, low density lipoprotein cholesterol, high density lipoprotein cholesterol, apoprotein AI, and apoprotein B were measured in 64 patients with systemic lupus erythematosus to assess the risk factors for vascular disease. The relation between the lipid profile, steroid treatment, the presence of anticardiolipin antibodies, and the prevalence of vascular disease was examined. Raised concentrations of triglyceride and apoprotein B were seen in those patients treated with more than the equivalent of 10 mg prednisolone a day in the six months before testing. An increase in vascular disease was found only in the subgroup of patients with increased triglycerides who also expressed anticardiolipin antibodies. This study confirms the association between treatment with high doses of steroids in lupus and the development of an atherogenic plasma lipid profile. The presence of anticardiolipin antibodies compounds the risk of developing vascular disease.

Full text

PDF
152

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alarcón-Segovia D. Pathogenetic potential of antiphospholipid antibodies. J Rheumatol. 1988 Jun;15(6):890–893. [PubMed] [Google Scholar]
  2. Asherson R. A., Derksen R. H., Harris E. N., Bingley P. J., Hoffbrand B. I., Gharavi A. E., Kater L., Hughes G. R. Large vessel occlusion and gangrene in systemic lupus erythematosus and "lupus-like" disease. A report of six cases. J Rheumatol. 1986 Aug;13(4):740–747. [PubMed] [Google Scholar]
  3. Avogaro P., Bon G. B., Cazzolato G., Quinci G. B. Are apolipoproteins better discriminators than lipids for atherosclerosis? Lancet. 1979 Apr 28;1(8122):901–903. doi: 10.1016/s0140-6736(79)91375-8. [DOI] [PubMed] [Google Scholar]
  4. Bonfiglio T. A., Botti R. E., Hagstrom J. W. Coronary arteritis, occlusion, and myocardial infarction due to lupus erythematosus. Am Heart J. 1972 Feb;83(2):153–158. doi: 10.1016/0002-8703(72)90133-0. [DOI] [PubMed] [Google Scholar]
  5. Bulkley B. H., Roberts W. C. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med. 1975 Feb;58(2):243–264. doi: 10.1016/0002-9343(75)90575-6. [DOI] [PubMed] [Google Scholar]
  6. Byron M. A., Allington M. J., Chapel H. M., Mowat A. G., Cederholm-Williams S. A. Indications of vascular endothelial cell dysfunction in systemic lupus erythematosus. Ann Rheum Dis. 1987 Oct;46(10):741–745. doi: 10.1136/ard.46.10.741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cathcart M. K., Morel D. W., Chisolm G. M., 3rd Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. J Leukoc Biol. 1985 Aug;38(2):341–350. doi: 10.1002/jlb.38.2.341. [DOI] [PubMed] [Google Scholar]
  8. Ettinger W. H., Goldberg A. P., Applebaum-Bowden D., Hazzard W. R. Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med. 1987 Sep;83(3):503–508. doi: 10.1016/0002-9343(87)90762-5. [DOI] [PubMed] [Google Scholar]
  9. Freyssinet J. M., Gauchy J., Cazenave J. P. The effect of phospholipids on the activation of protein C by the human thrombin-thrombomodulin complex. Biochem J. 1986 Aug 15;238(1):151–157. doi: 10.1042/bj2380151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun;18(6):499–502. [PubMed] [Google Scholar]
  11. Haider Y. S., Roberts W. C. Coronary arterial disease in systemic lupus erythematosus; quantification of degrees of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years. Am J Med. 1981 Apr;70(4):775–781. doi: 10.1016/0002-9343(81)90532-5. [DOI] [PubMed] [Google Scholar]
  12. Hamsten A., Norberg R., Björkholm M., de Faire U., Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet. 1986 Jan 18;1(8473):113–116. doi: 10.1016/s0140-6736(86)92258-0. [DOI] [PubMed] [Google Scholar]
  13. Harris E. N., Gharavi A. E., Asherson R. A., Boey M. L., Hughes G. R. Cerebral infarction in systemic lupus: association with anticardiolipin antibodies. Clin Exp Rheumatol. 1984 Jan-Mar;2(1):47–51. [PubMed] [Google Scholar]
  14. Harris E. N., Gharavi A. E., Boey M. L., Patel B. M., Mackworth-Young C. G., Loizou S., Hughes G. R. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 1983 Nov 26;2(8361):1211–1214. doi: 10.1016/s0140-6736(83)91267-9. [DOI] [PubMed] [Google Scholar]
  15. Homcy C. J., Liberthson R. R., Fallon J. T., Gross S., Miller L. M. Ischemic heart disease in systemic lupus erythematosus in the young patient: report of six cases. Am J Cardiol. 1982 Feb 1;49(2):478–484. doi: 10.1016/0002-9149(82)90528-8. [DOI] [PubMed] [Google Scholar]
  16. Inkeles S., Eisenberg D. Hyperlipidemia and coronary atherosclerosis: a review. Medicine (Baltimore) 1981 Mar;60(2):110–123. doi: 10.1097/00005792-198103000-00004. [DOI] [PubMed] [Google Scholar]
  17. Isenberg D. A., Williams W., Le Page S., Swana G., Feldman R., Addison I., Bakimer R., Shoenfeld Y. A comparison of autoantibodies and common DNA antibody idiotypes in SLE patients and their spouses. Br J Rheumatol. 1988 Dec;27(6):431–435. doi: 10.1093/rheumatology/27.6.431. [DOI] [PubMed] [Google Scholar]
  18. Jensen G., Sigurd B. Systemic lupus erythematosus and acute myocardial infarction. Chest. 1973 Nov;64(5):653–654. doi: 10.1378/chest.64.5.653. [DOI] [PubMed] [Google Scholar]
  19. Lupu C., Calb M. Changes in the platelet surface charge in rabbits with experimental hypercholesterolemia. Atherosclerosis. 1988 Jul;72(1):77–82. doi: 10.1016/0021-9150(88)90065-2. [DOI] [PubMed] [Google Scholar]
  20. Mackworth-Young C. G., Loizou S., Walport M. J. Antiphospholipid antibodies and disease. Q J Med. 1989 Sep;72(269):767–777. [PubMed] [Google Scholar]
  21. Noma A., Yokosuka T., Kitamura K. Plasma lipids and apolipoproteins as discriminators for presence and severity of angiographically defined coronary artery disease. Atherosclerosis. 1983 Oct;49(1):1–7. doi: 10.1016/0021-9150(83)90002-3. [DOI] [PubMed] [Google Scholar]
  23. Pengo V., Thiagarajan P., Shapiro S. S., Heine M. J. Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood. 1987 Jul;70(1):69–76. [PubMed] [Google Scholar]
  24. Rubin L. A., Urowitz M. B., Gladman D. D. Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med. 1985 Apr;55(216):87–98. [PubMed] [Google Scholar]
  25. Spiera H., Rothenberg R. R. Myocardial infarction in four young patients with SLE. J Rheumatol. 1983 Jun;10(3):464–466. [PubMed] [Google Scholar]
  26. Sturfelt G., Nived O., Norberg R., Thorstensson R., Krook K. Anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum. 1987 Apr;30(4):382–388. doi: 10.1002/art.1780300404. [DOI] [PubMed] [Google Scholar]
  27. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  28. Vergani C., Trovato G., Dioguardi N. Serum total lipids, lipoproteins cholesterol, apoproteins A and B in cardiovascular disease. Clin Chim Acta. 1978 Jul 1;87(1):127–133. doi: 10.1016/0009-8981(78)90066-9. [DOI] [PubMed] [Google Scholar]
  29. Vismara A., Meroni P. L., Tincani A., Harris E. N., Barcellini W., Brucato A., Khamashta M., Hughes G. R., Zanussi C., Balestrieri G. Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus. Clin Exp Immunol. 1988 Nov;74(2):247–253. [PMC free article] [PubMed] [Google Scholar]
  30. Zilversmit D. B. Atherogenesis: a postprandial phenomenon. Circulation. 1979 Sep;60(3):473–485. doi: 10.1161/01.cir.60.3.473. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES